Hello stephenj and All,
The following information generally does not consider the fact that the drugs being discussed are illegal for venues that subscribe to the rules promulgated by WADA and USADA and other organizations. It appears that it is too early to say what effect various drugs (such as testosterone, growth hormone, and EPO) will have on longevity and we will need to wait until the human 'early adopters' get sick, die, or survive ...... or perhaps get some clues from animal studies. My personal view is that because of the dollar value of the global testosterone market ($3.4 billion in 2022) we do have to be wary of the possibility of skewed testosterone studies funded to support greater sales of testosterone.
=========================================
It appears that you are disagreeing with the data reduction in the authors study because of their Standard Deviation and Coefficient of Variance values.
stephenj stated: "In addition to being a Dad, Im also molecular biologist who actually knows about this stuff."
With that in mind I appreciate your thoughtful criticism of the study I posted ...... but will leave the defense of the study to the authors.
Could you post some studies contradicting the referenced study .... that is .... studies showing that men's testosterone is not declining historically?
It appears there is a relationship between sperm count and testosterone. Is it reasonable to associate sperm count lowering historically with testosterone levels lowering historically?
https://www.ncbi.nlm.nih.gov/pubmed/26789272 Excerpts:
"
There was a significant decline in sperm concentration (-3.55, 95% CI -4.87, -2.23; p < 0.001), total motility (-1.23, 95% CI -1.65, -0.82; p < 0.001), total count (-10.75, 95% CI -15.95, -5.54; p < 0.001) and total motile count (-9.43, 95% CI -13.14, -5.73; p < 0.001). "
"This report demonstrates a decline in semen quality among young adult men in the Boston area who were attending or completed a college education during the past 10 years, and requires further study." [emphasis added]
stephenj wrote in part:
"And here is some data from that study.... Interesting how they got those 'trends' isn't it? THIS IS WHY YOU HAVE TO READ THE PEER REVIEW ARTICLE AND NOT JUST A SUMMARY!!!! Take a look at their SD and CVs...They are all in the original paper. "
More in line with your comments ..... this study below proposes a thoughtful approach to prescribing Testosterone to older men ....
(and you are welcome to read the all of the citations and other articles that pertain to this one too)
https://www.ncbi.nlm.nih.gov/...articles/PMC4707424/
Excerpts:
"Treatment for hypogonadism is on the rise, particularly in the aging population. Yet treatment in this population represents a unique challenge to clinicians. The physiology of normal aging is complex and often shares the same, often vague, symptoms of hypogonadism. In older men, a highly prevalent burden of comorbid medical conditions and polypharmacy complicates the differentiation of signs and symptoms of hypogonadism from those of normal aging, yet this differentiation is essential to the diagnosis of hypogonadism.
Even in older patients with unequivocally symptomatic hypogonadism, the clinician must navigate the potential benefits and risks of treatment that are not clearly defined in older men. More recently, a greater awareness of the potential risks associated with treatment in older men, particularly in regard to cardiovascular risk and mortality, have been appreciated with recent changes in the US Food and Drug Administration recommendations for use of testosterone in aging men."
"
Testosterone has become one of the most widely prescribed medications in the USA, increasing five-fold according to 2011 data. This increase has resulted in the dramatic growth of the testosterone replacement therapy (TRT) sector of the pharmaceutical industry from US$18 million in the 1980s to US$1.6 billion in 2011 [
Handelsman, 2013]. The reason is multifactorial, but can partly be attributed to the continued growth of the population over 65 years of age and a greater awareness of medical comorbidities more prevalent with age and associated with low testosterone, such as metabolic syndrome (MetS) and cardiovascular disease (CVD) [
Traish et al. 2009a,
2009b]."
"The authors encourage clinicians to only offer TRT to men diagnosed with symptomatic hypogonadism based upon a careful history demonstrating clear symptoms along with convincing laboratory data, and only after a thorough discussion of the uncertain benefits and possible risks of treatment. Informing patients of the recent FDA statement regarding TRT in aging men is of utmost importance in the current healthcare climate, particularly because testosterone use for this population may now be considered ‘off-label’.
With these caveats, the authors also want to reiterate the vast literature of known and proven benefits of testosterone normalization, which must also be carefully considered during the decision of whether or not to offer treatment. The best approach to TRT for the population of older hypogonadal men is probably one of full disclosure and shared decision-making." [emphasis added]
Go to: Footnotes
Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest statement: The authors declare that there is no conflict of interest.
Cheers, Neal
+1 mph Faster